Prosecution of Joint Patents. As between Dimension and Bayer, the Parties agree as follows:
Prosecution of Joint Patents. The party having the responsibility to file, prosecute and maintain Joint Patents under Article 6.3 shall comply with the procedure set out in Article 6.6.1, and the other Party shall cooperate as set out in Article 6.6.1.
Prosecution of Joint Patents. Calithera shall be responsible for obtaining, preparing, filing, prosecuting and maintaining Patent Rights, in appropriate countries in the Territory, including the countries reasonably requested by HPP, Covering Joint Inventions (“Joint Patents”). The out-of-pocket costs and expenses incurred to obtain, prosecute and maintain Joint Patents shall be [***]. Calithera shall keep HPP informed of the status of all pending Joint Patents. In the event that HPP believes that such patent strategy would have an unreasonable, adverse, economic effect on High Point’s rights under this Agreement (including inventorship or the value of any rights that HPP may obtain under Section 12.5), HPP may elect to submit the dispute to an independent Third Party patent counsel mutually agreed by Calithera and HPP, at HPP’s cost and expense. If such patent counsel determines that such patent strategy would have an unreasonable, adverse economic effect on High Point’s rights under this Agreement (including inventorship or the value of any rights that HPP may obtain under Section 12.5), then Calithera shall incorporate comments and adjust patent strategy as advised by such independent Third Party patent counsel, and Calithera shall [***]. Calithera shall not abandon any Joint Patent without at least thirty (30) days’ prior notice to HPP. If Calithera determines to abandon any Joint Patent in all or any portion of the Territory (the “Abandoned Joint Patent”), Calithera shall notify HPP of such determination. If HPP wishes to continue to prosecute and maintain the Abandoned Joint Patent, Calithera shall have the option to continue to prosecute and maintain the Abandoned Joint Patent at its expense or allow HPP to have the sole right, but not the obligation, to continue to prosecute and maintain the Abandoned Joint Patent [***]. Notwithstanding anything to the contrary, Calithera shall have the option to regain control of prosecution and maintenance of an Abandoned Joint Patent at any time, subject to [***] and [***] for such Abandoned Joint Patent. If Calithera or HPP elects to continue to prosecute and maintain any Abandoned Joint Patent, the other shall reasonably cooperate to transfer prosecution and maintenance of such Abandoned Joint Patent.
Prosecution of Joint Patents. Prior to preparation and filing of any Joint Patent, the Parties shall consult with one another and mutually agree upon a lead Party to file, prosecute and maintain such Joint Patent under the names of both Array and Ono. The Joint Patents shall be prepared and prosecuted by a mutually acceptable patent law firm and allocation of costs for preparation, filing, prosecution and maintenance shall be agreed by the Parties prior to preparation and filing of such Joint Patent. Notwithstanding the foregoing, either Party may elect not to support the filing, prosecution and maintenance of all or part of any Joint Patent in any country in the world.
Prosecution of Joint Patents. The JDC shall determine which party shall be responsible for obtaining, prosecuting and/or maintaining patents and patent applications, in appropriate countries in the Territory, covering Joint Inventions owned by Quark and Pfizer (“Joint Patents”). The out-of-pocket costs and expenses incurred to obtain, prosecute and maintain Joint Patents shall be: (a) [ * ], and (b) [ * ]. Either party may decline to bear its share of the costs and expenses to file, prosecute and/or maintain any particular Joint Patent in one or more countries. In that case, the other party may undertake the responsibility for filing, prosecuting and/or maintaining such Joint Patent at its own expense, and if it does so, the declining party shall assign to the other party all its right, title and interest to any such Joint Patent(s), and upon such assignment such Joint Patent(s) shall become solely Pfizer Patent Rights or Quark Patent Rights, as the case may be.
Prosecution of Joint Patents. (a) Akebia will have the first right of election to file patent applications for Joint Inventions. If Akebia declines to file such applications then Licensee may do so. On a semi-annual basis, Akebia shall provide to Licensee a written summary of the status of all Akebia Patents, including patent applications within Akebia Patents in the Territory. On the reasonable request of Xxxxxx, Licensee shall cooperate with Akebia in connection with the prosecution of all patent applications included within Joint Patents.
Prosecution of Joint Patents. The Joint Steering Committee shall determine, with respect to any particular Joint IP, whether and how to prepare and prosecute patent applications directed to the Joint IP (“Joint Patent Rights”). Unless otherwise decided by the Joint Steering Committee, the parties shall share equally in the costs of preparing and prosecuting such patent applications. However, if one party decides not to share in these costs, then it shall assign its rights in such patent application(s) to the other party for a reasonable price to be negotiated. The assignee shall then have the right to take over full control of preparing and prosecuting the patent applications and maintaining any patents.
Prosecution of Joint Patents. As between the Parties, (i) LaNova will have the first right, but not the obligation, to control and manage the Prosecution of all Joint Patents in the LaNova Territory, and (ii) TPTX will have the first right, but not the obligation, to control and manage the Prosecution of all Joint Patents in the TPTX Territory, in each case (i) and (ii), at the Prosecuting Party’s sole cost and expense and by counsel of its own choice. Each such Prosecuting Party will consult with the other Party as to the Prosecution of Joint Patents reasonably prior to any deadline or action with any patent office, will furnish to the other Party copies of all relevant drafts and documents reasonably in advance of such consultation, and will consider in good faith all reasonable requests or suggestions of the other Party with respect to such drafts or with respect to strategies for Prosecuting any such Joint Patents. The Parties will attempt in good faith to reach mutual agreement as to all matters concerning strategies for Prosecuting Joint Patents. Each such Prosecuting Party will keep the other Party reasonably informed of progress with regard to the Prosecution of Joint Patents, will provide to the other Party copies of all material patent office submissions within a reasonable amount of time (but not more than [***] days) following submission thereof by such Prosecuting Party. In the event that the Prosecuting Party desires to abandon or cease the Prosecution of any Joint Patent in any country in the Prosecuting Party’s respective territory, the Prosecuting Party will provide reasonable prior written notice to the other Party of such intention to abandon (which notice will, to the extent possible, be given no later than [***] days prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office). In such case, at the other Party’s sole discretion, upon written notice to the Prosecuting Party from the other Party, the other Party may elect to [***] = Certain Confidential Information Omitted continue the Prosecution of any such Joint Patent, at its sole cost and expense and by counsel of its own choice.
Prosecution of Joint Patents. CISTRON shall have sole responsibility for the filing, prosecuting and maintaining of appropriate worldwide patents and patent applications for the JOINT PATENTS using counsel reasonably acceptable to DUKE, and CISTRON shall pay all expenses incurred in such activities. CISTRON shall keep DUKE advised as to the prosecution of such applications by forwarding to DUKE copies of all official correspondence relating thereto. CISTRON and DUKE agree to cooperate in the prosecution of worldwide JOINT PATENTS to insure that the applications reflect, to the best of both parties' knowledge, all items of commercial and technical interest and importance. CISTRON agrees to allow DUKE sufficient time to make suggestions with regard to patent prosecution and to give such suggestions reasonable consideration. CISTRON will not abandon, nor allow to go abandoned, any patent application that is included in JOINT PATENTS without first giving DUKE written notice that CISTRON intends to abandon such an application, such notice to be given in sufficient time for DUKE to assume responsibility for prosecution of such JOINT PATENTS. In the event that DUKE assumes responsibility for prosecuting any JOINT PATENT that CISTRON intends to abandon, CISTRON shall lose all rights in such application, and DUKE shall assume full financial responsibility for the prosecution and maintenance of such an application.
Prosecution of Joint Patents. Collagenex will have first right to control the preparation, filing and prosecution of joint patents and patent applications and the maintenance of patents issuing thereon, and QuatRx shall cooperate reasonably with Collagenex in such prosecution efforts. Collagenex shall pay all expenses in connection with its preparation, filing and prosecution of such patents. Collagenex shall, from time to time (no more often than once per calendar quarter), notify QuatRx of the actual amount of out-of-pocket expenses incurred in such efforts, and QuatRx shall promptly thereafter pay Collagenex 50% of such out-of-pocket
